Loss of TP53 function has been shown to negatively affect disease outcome in other solid tumours such as bladder carcinomas, while in breast cancer, for example, TP53 mutation has been linked to improved prognosis in patients treated with chemotherapy but poor prognosis in those treated with hormone therapy12. Here, TP53 is linked to urinary bladder carcinoma.